Vidarabine is neither a potent nor a selective AC5 inhibitor |
| |
| Affiliation: | 1. Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, Winsløwparken 21, DK-5000 Odense C, Denmark;2. Department of Neurosurgery, Neurocenter and Regenerative Neuroscience Cluster, University of Berne, CH-3010 Berne, Switzerland;1. Stefan S Nicolau Institute of Virology, Romanian Academy, Bucharest, Romania;2. Faculty of Chemistry, University of Bucharest, Romania;3. Institute of Cardiovascular Diseases Prof. Dr. C.C. Iliescu, Microbiology Department, Bucharest, Romania;4. University of Orleans, ICOA-UMR7311, CNRS, France;1. Xinjiang Fishery Research Institute, 614 West Xihong Road, Urumqi 830000, China;2. Institute of Evolution & Marine Biodiversity, Ocean University of China, 5 Yushan Road, Qingdao 266003, China;3. Fisheries College of Huazhong Agricultural University, 1 Shizishan Street, Wuhan 430070, China;1. Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Ga;2. Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Ga |
| |
| Abstract: | Vidarabine was the first clinically approved antiviral drug, but due to safety and efficacy issues the drug is currently only used topically for herpes virus keratitis. Scientific interest in vidarabine has been recently renewed due to the fact that the compound exhibits beneficial effects in animal models of heart failure and cancer, replicating effects of the knockout of adenylyl cyclase 5 (AC5). Therefore, vidarabine has been suggested to mediate these effects via selective inhibition of AC5. Based on these results, clinical studies with vidarabine in humans for heart failure and cancer have been proposed. Here, evidence is presented that vidarabine is neither a potent nor a selective AC5 inhibitor. Greatest caution should be exerted when proposing new mechanisms of actions and clinical uses for vidarabine. |
| |
| Keywords: | Adenylyl cyclase 5 Heart failure Cancer P-site inhibitor Vidarabine AC" },{" #name" :" keyword" ," $" :{" id" :" kw0035" }," $$" :[{" #name" :" text" ," _" :" adenylyl cyclase |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
